Innodia Inc.
ID 1101 enters Phase Ib clinical trial
Published in Lab Business Week, May 8th, 2005
Innodia Inc, a biopharmaceutical company engaged in bringing to market novel drugs for the treatment of type 2 diabetes and related diseases, has announced the initiation of a Phase Ib escalating multiple-dose human clinical trial with ID 1101, its lead drug candidate for the treatment of type 2 diabetes. The company also announced positive safety results on the recently completed single-dose Phase Ia clinical trial with ID 1101.
ID 1101 is an orally active antidiabetic drug candidate with a unique dual mode of action; it increases insulin secretion by the pancreas and decreases peripheral insulin resistance observed in type 2 diabetes. The increased insulin secretion...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2005-05-08)
More Articles from Lab Business Week
- AEterna Zentaris, Inc.
Atrium Biotechnologies files final prospectus for $75M IPO - Access Pharmaceuticals, Inc.
Pharmaceutical company reports loss of $0.18 per share - Aeterna Zentaris Inc.
Atrium Biotechnologies finishes initial public, secondary offering of $75M - Alexion Pharmaceuticals, Inc.
Pharmaceutical firm files resale registration statement for notes - Alltracel Pharmaceuticals Plc.
Pharmaceutical company reports 355% increase in revenue - Almirall
Pharmaceutical company reaches sales of EUR900 million in 2004 - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
